TransMedics Group financials
$84.07+1.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 28 |
|---|---|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M | $25.6M | $23.6M |
| Gross profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M | $16.6M | $13.9M |
| Gross margin | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | 64.9% | 58.7% |
| Operating income | $108.6M | $37.5M | -$28.7M | -$31.4M | -$39.4M | -$26.4M | -$29.6M |
| Net income | $190.3M | $35.5M | -$25.0M | -$36.2M | -$44.2M | -$28.7M | -$33.5M |
| Net margin | 31.4% | 8.0% | −10.4% | −38.8% | −146.1% | −112.1% | −142.1% |
| Diluted EPS | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 |
| EBITDA | $135.8M | $57.3M | -$20.6M | -$28.0M | -$37.6M | -$24.8M | -$28.4M |
| Operating cash flow | $192.8M | $48.8M | -$13.0M | -$45.8M | -$28.9M | -$30.3M | -$32.3M |
| Free cash flow | $133.6M | -$80.9M | -$164.9M | -$57.7M | -$32.4M | -$30.7M | -$32.5M |
| Diluted shares | 40.5M | 35.2M | 32.5M | 29.6M | 27.6M | 24.7M | 14.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $488.4M | $336.6M | $394.8M | $201.2M | $25.6M | $24.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $66.9M | $101.1M |
| Total debt | $512.4M | $509.3M | $506.2M | $58.7M | $35.2M | $34.7M |
| Total assets | $1.07B | $804.1M | $706.0M | $277.1M | $134.9M | $152.0M |
| Total liabilities | $595.3M | $575.5M | $568.8M | $89.8M | $67.0M | $48.1M |
| Shareholders' equity | $473.1M | $228.6M | $137.2M | $187.4M | $67.9M | $103.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology